


INVITATION

18 MAY 2023

Update on the role of ECP in the management of acute & chronic GvHD

King Hussein Cancer Center, Amman, Jordan



This information is intended for healthcare professionals in the Middle East and North Africa

Agenda

Time: 17:30 – 20:15 EET

Moderator	Dr Khalid Halahleh , King Hussein Cancer Center, Jordan
17:30 – 17:35	Introduction Dr Khalid Halahleh , King Hussein Cancer Center, Jordan
17:35 – 18:00	Use of ECP in acute and chronic GvHD Prof Robert Zeiser , University Hospital Freiburg, Germany
18:00 – 18:45	Combination of therapies in GvHD Prof Robert Zeiser , University Hospital Freiburg, Germany
18:45 – 19:15	Local Experience in King Hussein Cancer Center Dr Khalid Halahleh , King Hussein Cancer Center, Jordan
19:15 – 19:30	Q & A
19:30	Dinner

To confirm your attendance please email daniel.riman@mealigroup.com or amira.chakroun@mealigroup.com

ECP: Extracorporeal Photopheresis, GvHD: Graft vs Host Disease

All speakers are subject to contract.

This is a commercial programme run by Mealis in collaboration with Therakos (UK) Ltd

[Privacy policy](#)



Follow the
Therakos Institute 

For more information on THERAKOS ECP Immunomodulation™ please visit www.therakos.eu
Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company. Other brands are trademarks of a Mallinckrodt company or their respective owners.

© 2023 Mallinckrodt. Item code: JO-2300001. Date of preparation: April 2023.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our privacy policy provides additional information.

